DS3610 enters clinical development in patients with advanced solid tumors as first STING agonist ADC in industry-leading ADC portfolio of Daiichi Sankyo

Source: marketscreener The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.